These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27548911)

  • 21. Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
    Pelliccia F; Greco C; Gaudio C; Rosano G; Vitale C; Marazzi G; Rollini F; Angiolillo DJ
    J Thromb Thrombolysis; 2015 Oct; 40(3):331-9. PubMed ID: 25761430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges of antiplatelet therapy in patients who require anticoagulation.
    Henkel DM; Holmes DR
    J Invasive Cardiol; 2009 Apr; 21(4):186-9. PubMed ID: 19342758
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous chest wall hematoma with dual antiplatelet therapy.
    Bevan P; Menon A; Bunton R
    Can J Cardiol; 2014 Feb; 30(2):247.e1-2. PubMed ID: 24290862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation.
    Helft G
    Arch Cardiovasc Dis; 2013 May; 106(5):271-3. PubMed ID: 23769401
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
    Shalaev SV
    Kardiologiia; 2003; 43(6):84-7. PubMed ID: 13677328
    [No Abstract]   [Full Text] [Related]  

  • 30. Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review.
    Chang KW; Arbit B; Hsu JC
    Int J Cardiol; 2017 Sep; 243():263-269. PubMed ID: 28595745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
    Peace AJ; Tedesco AF; Foley DP; Dicker P; Berndt MC; Kenny D
    J Thromb Haemost; 2008 Dec; 6(12):2027-34. PubMed ID: 18823340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
    Bonello L; Lemesle G; De Labriolle A; Barragan P; Camoin-Jau L; Paganelli F
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1525-32. PubMed ID: 19954314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
    Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
    Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
    Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.